Dianthus Therapeutics Inc.
$ 108.92
-0.91%
07 Aug - close price
- Market Cap 5,954,246,000 USD
- Current Price $ 108.92
- High / Low $ 113.35 / 106.88
- Stock P/E N/A
- Book Value 21.39
- EPS -4.24
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.26 %
- 52 Week High 114.55
- 52 Week Low 18.08
About
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Analyst Target Price
$137.62
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-03-09 | 2025-11-05 | 2025-08-07 | 2025-05-12 | 2025-03-11 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 |
| Reported EPS | -0.9 | -0.85 | -1.43 | -0.97 | -0.88 | -0.82 | -0.81 | -0.74 | -0.51 | -0.54 | -0.71 | -3.78 |
| Estimated EPS | -0.93 | -1.1 | -1.0314 | -0.86 | -0.86 | -0.71 | -0.76 | -0.6 | -0.55 | -0.44 | -1.01 | -0.56 |
| Surprise | 0.03 | 0.25 | -0.3986 | -0.11 | -0.02 | -0.11 | -0.05 | -0.14 | 0.04 | -0.1 | 0.3 | -3.22 |
| Surprise Percentage | 3.2258% | 22.7273% | -38.6465% | -12.7907% | -2.3256% | -15.493% | -6.5789% | -23.3333% | 7.2727% | -22.7273% | 29.703% | -575% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DNTH
2026-08-09 08:09:30
The California State Teachers Retirement System significantly increased its stake in Dianthus Therapeutics (DNTH) by 155.5% in the first quarter, now owning 40,584 shares valued at $3.4 million. Despite this institutional confidence and generally positive analyst ratings, the company faces risks including ongoing losses, missing quarterly EPS expectations, and substantial insider selling. Dianthus Therapeutics focuses on developing complement therapeutics for autoimmune and inflammatory diseases and currently holds a "Moderate Buy" consensus rating among analysts.
2026-08-08 07:40:54
Marino Garcia, CEO of Dianthus Therapeutics (NASDAQ:DNTH), sold 166,000 shares totaling approximately $17.95 million on August 7, 2026, following the exercise of stock options. The sale occurred near the stock's 52-week high after a significant 481% return, aligning with an analyst valuation suggesting the stock is overvalued. Dianthus also recently announced a Phase 3 EMERGE trial and received positive analyst ratings from Raymond James, Guggenheim, and TD Cowen.
2026-08-08 05:41:22
Dianthus Therapeutics CEO Marino Garcia sold approximately $17.95 million worth of common stock on August 7, 2026, through a pre-planned trading strategy. This sale occurred while the stock was trading near its 52-week high after a significant 481% return over the past year. Concurrently, Dianthus Therapeutics announced the initiation of its Phase 3 EMERGE trial and received positive analyst ratings from Raymond James, Guggenheim, and TD Cowen.
2026-08-08 01:41:22
This article reports on Dianthus Therapeutics, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of 40,000 shares of common stock with an aggregate market value of $4,396,800.00, resulting from the exercise of stock options. The filing has a neutral impact and sentiment according to AI-generated analysis.
2026-08-07 23:40:54
Dianthus Therapeutics CEO and President Marino Garcia exercised options for 166,000 shares at $8.44 each, increasing his direct holdings. Subsequently, he sold these 166,000 shares at prices ranging from $107.49 to $110.76, reducing his direct common stock holdings to 65,292 shares. The total value of the shares disposed was approximately $17.97 million.
2026-08-07 23:40:54
Dianthus Therapeutics CEO Marino Garcia sold 166,000 shares of the company's stock for approximately $17.95 million, reducing his direct ownership by 71.77%. The sale occurred on August 7th, with shares trading at $108.11 on average. Despite missing recent earnings estimates, the company's stock is near its 12-month high, and analysts maintain a "Moderate Buy" rating with an average price target of $124.27.
